MedWorks, Author at MedWorks Media

Efficacy and Safety of Basimglurant as Adjunctive Therapy for Major Depression: A Randomized Clinical Trial

By MedWorks|2016-07-07T16:09:51-07:00July 7th, 2016|We Know Psychiatry|

Efficacy and Safety of Basimglurant as Adjunctive Therapy for Major Depression: A Randomized Clinical Trial Jorge A. Quiroz, MD, MBA; Paul Tamburri, PharmD; Dennis Deptula, PhD; Ludger Banken, PhD; Ulrich Beyer, PhD; Michael Rabbia, MA; Nikhat Parkar, MSc; Paulo Fontoura, MD, PhD; Luca Santarelli, MD ABSTRACT Importance Antagonism of the postsynaptic metabotropic glutamate subtype 5 receptor is a novel approach to modulate glutamatergic function and has proven efficacy in [...]

0

NYU’s Medical School Shutters Eight Cannabis/Ecstasy Studies

By MedWorks|2016-06-28T17:08:31-07:00June 28th, 2016|We Know Psychiatry|

New York University’s medical school has quietly shut down eight studies at its prominent psychiatric research center and parted ways with a top researcher after discovering a series of violations in a study of an experimental, mind-altering drug. A subsequent federal investigation found lax oversight of study participants, most of [...]

0

ASSOCIATIONS BETWEEN CANNABIS & TOBACCO USE IN EARLY MIDLIFE: UPDATE

By MedWorks|2016-06-08T15:53:54-07:00June 8th, 2016|We Know Psychiatry|

After major policy changes in the United States, policymakers, health care professionals, and the general public seek information about whether recreational cannabis use is associated with physical health problems later in life, as compared with numerous known risks of tobacco use. Participants belonged to a representative birth cohort of [...]

0

Associations Between Cannabis & Tobacco Use in Early Midlife: Bad News for Dentists

By MedWorks|2016-06-04T23:01:55-07:00June 4th, 2016|We Know Psychiatry|

A Longitudinal Comparison of Persistent Cannabis vs Tobacco Users Marijuana users might glean some good news from a soon to be published report comparing Cannabis vs. tobacco users, except when it comes to their dentists. After major policy changes in the United States, policymakers, health care professionals, and the general [...]

0

New Evidence Suggests that Children with ADHD and Autistic Spectrum Disorder may have lower Omega-3 and Omega-6 Polyunsaturated Fatty Acid Levels

By MedWorks|2016-05-31T13:36:02-07:00May 31st, 2016|We Know Psychiatry|

By Natalie Parletta, Theophile Niyonsenga, and Jacques Duff Abstract Background There is evidence that children with Attention Deficit Hyperactivity Disorder (ADHD) and Autistic Spectrum Disorder (ASD) have lower omega-3 polyunsaturated fatty acid (n-3 PUFA) levels compared with controls and conflicting evidence regarding omega-6 (n-6) PUFA levels. Objectives This study investigated whether erythrocyte [...]

1

Attention-Deficit/Hyperactivity Disorder Trajectories From Childhood to Young Adulthood: Evidence From a Birth Cohort Supporting a Late-onset Syndrome

By MedWorks|2016-05-31T13:16:56-07:00May 31st, 2016|We Know Psychiatry|

By Arthur Caye; Thiago Botter-Maio Rocha, MD, MSc; Luciana Anselmi, PhD; Joseph Murray, PhD; Ana M. B. Menezes, PhD; Fernando C. Barros, PhD; Helen Gonçalves, PhD; Fernando Wehrmeister, PhD; Christina M. Jensen, MSc; Hans-Christoph Steinhausen, MD, PhD, DMSc; James M. Swanson, PhD; Christian Kieling, MD, PhD; Luis Augusto Rohde, MD, PhD ABSTRACT Importance The requirement of a childhood onset has always been a key criterion for the diagnosis of attention-deficit/hyperactivity disorder (ADHD) in adults, but [...]

0

As Opioid Prescribing Guidelines Tighten, Mindfulness Meditation Holds Promise for Pain Relief

By MedWorks|2016-05-21T16:46:47-07:00May 21st, 2016|We Know Psychiatry|

By Julie A. Jacob, MA Try nonpharmacologic and nonopioid therapies first, the Centers for Disease Control and Prevention (CDC) recommended in a recently published opioid prescribing guideline for primary care clinicians in outpatient settings (Dowell D et al. JAMA. 2016;315[15]:1624-1645). The CDC’s call for nonpharmacologic approaches may serve to heighten clinician interest in [...]

0

Shire Presents New Research into Binge Eating Disorder and ADHD

By MedWorks|2016-05-16T18:27:47-07:00May 16th, 2016|We Know Psychiatry|

Pharmaceutical heavyweight, Shire, best known in the US for its ADHD medications, presented new research on Binge Eating Disorder (B.E.D.) and Attention-Deficit/Hyperactivity Disorder (ADHD) at the American Psychiatric Association (APA) in Atlanta, GA, "demonstrating its ongoing commitment to furthering the understanding and management of psychiatric disorders," the company said in a [...]

0

Married Individuals Less Likely to Develop Alcohol Problems

By MedWorks|2016-05-16T14:04:41-07:00May 16th, 2016|We Know Psychiatry|

Monday, May 16, 2016. APA Meeting, Atlanta, GA. #APAAM16 For both men and women being married is associated with significantly reduced risk for alcohol use disorder compared to unmarried individuals. The protective effects of marriage are even stronger for people with a high family risk of alcoholism, according to a study [...]

0

Suicidality and Hostility following Involuntary Hospital Treatment

By MedWorks|2016-05-15T21:41:23-07:00May 15th, 2016|We Know Psychiatry|

By Domenico Giacco and Stefan Priebe Abstract Background Psychiatric patients showing risk to themselves or others can be involuntarily hospitalised. No data is available on whether following hospitalisation there is a reduction in psychopathological indicators of risk such as suicidality and hostility. This study aimed to assess changes in suicidality and [...]

0

About MedWorks